Jardiance 10mg, 30 Tablets (Empagliflozin) — Boehringer Ingelheim

Jardiance (Empagliflozin) — 30 Tablets

Jardiance is a premium, clinically established formulation of Empagliflozin developed by the renowned pharmaceutical global leader Boehringer Ingelheim. This product listing features a complete box containing 30 film-coated tablets (10 mg each), a highly utilized and standardized volume for evaluating modern metabolic pathways and advanced cardiovascular longevity strategies.

General Pharmaceutical & Manufacturer Information

• Brand Name: Jardiance
• Active Ingredient: Empagliflozin
• Dosage: 10 mg of Empagliflozin per tablet
• Package Size: 1 Box (30 film-coated tablets)
• CAS Number: 864070-44-0
• Molecular Formula: C23H27ClO7
• Form: Film-coated oral tablets
• Manufacturer: Boehringer Ingelheim Pharma GmbH & Co. KG, Germany

Anti-Aging & Longevity Properties (Metabolic Health & Cardiovascular Geroprotection)

In modern longevity and healthspan optimization, SGLT2 (sodium-glucose cotransporter 2) inhibitors like empagliflozin are heavily studied as prominent candidate geroprotectors. Rather than simply managing glycemic parameters, SGLT2 inhibitors target multiple core hallmarks of systemic aging.

1. SGLT2 Inhibition and Caloric Restriction Mimicry

Empagliflozin works selectively in the kidneys to block the reabsorption of glucose, promoting its excretion via urine. This consistent disposal of excess glucose and its associated calories mimics key physiological signaling pathways of caloric restriction, shifting cells into a state of maintenance, preservation, and repair.

2. Robust Cardiovascular and Renal Protection

Large-scale clinical evaluations (including the landmark EMPA-REG OUTCOME trial) have demonstrated that empagliflozin significantly reduces the risk of cardiovascular mortality, hospitalization for heart failure, and progressive kidney decline. It reduces systemic arterial stiffness and cardiac workload, safeguarding crucial organ systems against age-related degeneration.

3. Mitigation of Glycation and Systemic Inflammation (Inflammaging)

By flattening postprandial blood glucose spikes, Jardiance protects cellular membranes and functional proteins from advanced glycation end-products (AGEs). Furthermore, its metabolic modulation directly downregulates systemic inflammatory pathways, mitigating the chronic, low-grade inflammation that drives rapid tissue aging.

4. Upregulation of Ketogenesis and Cellular Energy Efficiency

SGLT2 inhibition mildly shifts cellular metabolism toward ketone body utilization. Ketones act as a highly efficient fuel source for both the heart and brain, generating fewer reactive oxygen species (ROS) during ATP production and supporting overall mitochondrial vitality.

Administration & Strict Disclaimer

In longevity and metabolic research protocols, Jardiance is typically administered once daily in the morning, with or without food. A 30-tablet pack provides a standard, convenient supply for consistent, multi-week tracking of metabolic and physiological parameters.

Strict Regulatory Disclaimer: This product is intended solely for laboratory research, in vitro evaluation, and analytical purposes. We do not provide medical advice, recommend specific protocols, or guarantee any therapeutic results. Nothing stated herein should be construed as a medical recommendation or a guarantee of efficacy in treating, curing, or preventing any disease. Any practical application of this compound must be strictly validated by independent research and overseen by a qualified professional.